Raadpleeg ook: 


PRM1201 is samengesteld uit zeven kruiden: Ligustrum lucidum WTAiton fructus (Nv Zhen Zi), Cistanche deserticola YCMa herba (Rou Cong Rong), Iphigenia indica (L.) A. Gray ex Kunth pseudobulb (San Ci Gu), Vitis quinquangularis Rehder wijnstok ( Ye Pu Tao Teng), Panax ginseng CAMey. wortel (Ren Sen), Akebia trifoliata (Thunb.) Koidz. fruit (Yu Zhi Zi), en Salvia miltiorrhiza Bunge-wortel (Dan Shen).

Raadpleeg Natuurapotheek voor deze kruidencombinatie.

14 juli 2021: Bron:  2021; 11: 618793. Published online 2021 Mar 3

De Chinese kruidenmix PRM1201 (bevat 7 verschillende kruiden) naast chemotherapie geeft na drie jaar 8,5 procent betere ziektevrije overleving voor patiënten met operabele darmkanker stadium III. Ook minder recidieven en betere kwaliteit van leven. Dit blijkt uit de resultaten van een placebo gecontroleerde gerandomiseerde studie bij totaal 370 darmkankerpatiënten. 
Chemotherapie is de standaard behandeling van darmkanker. Uit eerdere studies is gebleken dat de Chinese kruidenmix PRM1201 (bevat 7 verschillende kruiden) de werkzaamheid van chemotherapie verbetert bij gebruik in combinatie met Cetuximab of Bevacizumab bij patiënten met uitgezaaide darmkanker.

In deze placebo gecontroleerde gerandomiseerde studie werden patiënten die een volledige operatie hadden ondergaan voor stadium III darmkanker willekeurig toegewezen aan adjuvante chemotherapie (FOLFOX q2w gedurende 6 maanden, of CapeOx q3w gedurende 6 maanden) plus PRM1201 (chemo + PRM1201-groep) of adjuvante chemotherapie plus placebo (chemo + placebogroep).

Het primaire einddoel was ziektevrije overleving (DFS) en de secundaire einddoelen waren kwaliteit van leven (QOL) en toxiciteit.

  • Totaal 370 patiënten werden willekeurig toegewezen aan chemotherapie plus PRM1201-groep (n = 184) en chemotherapie plus placebogroep (n = 186).
  • Tot 30 oktober 2019 waren 96 voorvallen van een recidief, metastase of overlijden gemeld, waarvan 38 voorvallen in de groep chemotherapie plus PRM1201 en 58 voorvallen in de chemo + placebogroep.
  • Het 3-jaars ziektevrije-percentage was respectievelijk 77,1 procent en 68,6 procent in de chemo + PRM1201 groep en chemo + placebogroep (hazard ratio 0,63; 95% BI 0,42 tot 0,94). Een verbetering dus van 8,5 procent in overleving zonder recidief of uitzaaiingen.
  • De kwaliteit van leven van patiënten in de chemo + PRM1201-groep was significant verbeterd in termen van globale kwaliteit van leven, fysiek functioneren, rolfunctioneren, emotioneel functioneren, vermoeidheid en verlies van eetlust. De incidentie van graad 3 of 4 behandelingsgerelateerde bijwerkingen (TRAE's) was vergelijkbaar tussen de twee groepen.

Chemotherapie in combinatie met PRM1201 verbeterde de adjuvante behandeling van darmkanker. PRM1201 kan worden aanbevolen als een effectieve optie in de klinische praktijk.

An external file that holds a picture, illustration, etc.
Object name is fonc-11-618793-g002.jpg

Het volledige studierapport is gratis in te zien met gedetailleerde grafieken n beschrijvingen. En gepubliceerd in Frontiers Oncology. Hier het abstract:



Chemotherapy is the standard adjuvant treatment for colon cancer. Chinese herbal formula PRM1201 improves the efficacy of chemotherapy when used in combination with Cetuximab or Bevacizumab in patients with metastatic colorectal cancer. This study aims to explore the benefits of treatment with chemotherapy plus PRM1201 in the postoperative adjuvant setting.


In this parallel-group study, patients who had undergone curative resection for stage III colon cancer were randomly assigned to receive adjuvant chemotherapy (FOLFOX q2w for 6 months, or CapeOx q3w for 6 months) plus PRM1201 (chemo+PRM1201 group) or adjuvant chemotherapy plus placebo (chemo+placebo group). The primary endpoint was disease-free survival (DFS), and the secondary endpoints were quality of life (QOL) and toxicity.


A total of 370 patients were randomly assigned to chemotherapy plus PRM1201 group (n = 184) and chemotherapy plus placebo group (n = 186). Up to October 30, 2019, 96 events of recurrence, metastasis, or death had been reported, of which 38 events were in the group of chemotherapy plus PRM1201 and 58 events in the chemo+placebo group. The 3-year DFS rate was 77.1 and 68.6% in the chemo+PRM1201 and chemo+placebo group, respectively (hazard ratio , 0.63; 95% CI, 0.42 to 0.94). The QOL of patients in the chemo+PRM1201 group were significantly improved in terms of global quality of life, physical functioning, role functioning, emotional functioning, fatigue, and appetite loss. The incidence of grade 3 or 4 treatment-related adverse event (TRAEs) were similar between the two arms.


Chemotherapy in combination with PRM1201 improved the adjuvant treatment of colon cancer. PRM1201 can be recommended as an effective option in clinical practice.

Clinical Trial Registration Chinese Clinical Trials Registry, identifier ChiCTR-IOR-16007719.

Data Availability Statement

The original contributions presented in the study are included in the article/ Supplementary Material . Further inquiries can be directed to the corresponding authors.

Ethics Statement

The studies involving human participants were reviewed and approved by IRB of Shuguang Hospital affiliated with Shanghai University of TCM. The patients/participants provided their written informed consent to participate in this study.

Author Contributions

QL was involved in the conception and design of the study. RJ, NL, GC, HX, PZ, HML, JH, XY, HG, WY and QL were involved in provision of study materials or patients. RJ, YuZ, LHZ, YiZ, CW, XS, YF, HJL, HL, ZH, YL, YaZ and GH were involved in acquisition of data. RJ, QJ, ZL and WY were involved in data analysis and interpretation. RJ drafted the manuscript and QL, WY and NL were involved in the critical revision of the manuscript. All authors contributed to the article and approved the submitted version.


This research was supported by grants from the Key projects of the National Natural Science Foundation of China (No.82030118), Three-year Plan of Action for the Development of Traditional Chinese Medicine in Shanghai (ZY(2018-2020)-CCCX-2003-03), and key Projects of Shanghai Science and Technology Commission (16401970500).

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Supplementary Material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2021.618793/full#supplementary-material


1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesCA Cancer J Clin (2018) 68(6):394–424.  10.3322/caac.21492 [PubMed] [CrossRef[]
2. Labianca R, Merelli B. Screening and diagnosis for colorectal cancer: present and futureTumori (2010) 96(6):889–901. [PubMed[]
3. Grothey A, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, et al. . Duration of Adjuvant Chemotherapy for Stage III Colon CancerN Engl J Med (2018) 378(13):1177–88.  10.1056/NEJMoa1713709 [PMC free article] [PubMed] [CrossRef[]
4. Gupta GP, Massague J. Cancer metastasis: building a frameworkCell (2006) 127(4):679–95.  10.1016/j.cell.2006.11.001 [PubMed] [CrossRef[]
5. Cheng X, Huo J, Wang D, Cai X, Sun X, Lu W, et al. . Herbal Medicine AC591 Prevents Oxaliplatin-Induced Peripheral Neuropathy in Animal Model and Cancer PatientsFront Pharmacol (2017) 8344.  10.3389/fphar.2017.00344 [PMC free article] [PubMed] [CrossRef[]
6. Jiao L, Dong C, Liu J, Chen Z, Zhang L, Xu J, et al. . Effects of Chinese Medicine as Adjunct Medication for Adjuvant Chemotherapy Treatments of Non-Small Cell Lung Cancer PatientsSci Rep (2017) 7: 46524.  10.1038/srep46524 [PMC free article] [PubMed] [CrossRef[]
7. Lam W, Bussom S, Guan F, Jiang Z, Zhang W, Gullen EA, et al. . The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicitySci Transl Med (2010) 2(45):45ra59.  10.1126/scitranslmed.3001270 [PubMed] [CrossRef[]
8. Jia Ru HX, Wang Y, Zhou L, Sui H, Li Q, Ji Q. Effective ingredients, potential targets and mechanism in cancers treatment of Bushen Jiedu Sanjie RecipeTMR Cancer (2019) 2(1):133–42.  10.12032/PMR201800051 [CrossRef[]
9. Zhou L-H, Feng Y-Y, Wang Y, Sun X-T, Li C-P, Zhu H-R, et al. . Bushen Jiedu Sanjie Recipe alcohol extract inhibit cell proliferation through HIPK2-p53 signaling pathway in colorectal cancerChin J Tradit Chin Med Pharm (2017), 32(1) 32234–7.  CNKISUNBXYY.0.2017-01-065 []
10. S X-T, Feng Y-Y, Liu X, Wang Y, Zhou L-H, Deng W-L, et al. . Bushen Jiedu Sanjie Recipe inhibit invasion and metastasis of colorectal cancer through Wnt/β-catenin singaling pathwayActa Universitatis Traditionis Medicalis Sinensis Pharmacologiaeque Shanghai (2017), 31(1):4.  10.16306/j.1008-861x.2017.01.011 [CrossRef[]
11. Liu N, Wu C, Jia R, Cai G, Wang Y, Zhou L, et al. . Traditional Chinese Medicine Combined With Chemotherapy and Cetuximab or Bevacizumab for Metastatic Colorectal Cancer: A Randomized, Double-Blind, Placebo-Controlled Clinical TrialFront Pharmacol (2020) 11:478.  10.3389/fphar.2020.00478 [PMC free article] [PubMed] [CrossRef[]
12. Niezgoda HE, Pater JL. A validation study of the domains of the core EORTC quality of life questionnaireQual Life Res (1993) 2(5):319–25.  10.1007/BF00449426 [PubMed] [CrossRef[]
13. Jiao L, Xu J, Sun J, Chen Z, Gong Y, Bi L, et al. . Chinese Herbal Medicine Combined With EGFR-TKI in EGFR Mutation-Positive Advanced Pulmonary Adenocarcinoma (CATLA): A Multicenter, Randomized, Double-Blind, Placebo-Controlled TrialFront Pharmacol (2019) 10:732.  10.3389/fphar.2019.00732 [PMC free article] [PubMed] [CrossRef[]
14. Xu Y, Mao JJ, Sun L, Yang L, Li J, Hao Y, et al. . Association Between Use of Traditional Chinese Medicine Herbal Therapy and Survival Outcomes in Patients With Stage II and III Colorectal Cancer: A Multicenter Prospective Cohort StudyJ Natl Cancer Inst Monogr (2017) 2017(52):19–25.  10.1093/jncimonographs/lgx015 [PMC free article] [PubMed] [CrossRef[]
15. Liu SS, Shi Q, Li HJ, Yang W, Han SS, Zong SQ, et al. . Right- and left-sided colorectal cancers respond differently to traditional Chinese medicineWorld J Gastroenterol (2017) 23(42):7618–25.  10.3748/wjg.v23.i42.7618 [PMC free article] [PubMed] [CrossRef[]
16. Benson AB, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, et al. . American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon CancerJ Clin Oncol (2004) 22(16):3408.  10.1200/JCO.2004.05.063 [PubMed] [CrossRef[]
17. Des GG, Uzzan B, Morere JF, Perret G, Nicolas P. Duration of adjuvant chemotherapy for patients with non-metastatic colorectal cancerCochrane Database Syst Rev (2010) 65(1):1399–400.  10.1002/14651858.CD007046.pub2 [PubMed] [CrossRef[]
18. Schmoll HJ, Tabernero J, Maroun J, De FB, Price T, Van EC, et al. . Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III TrialJ Clin Oncol (2015) 33(32):3733–40.  10.1200/JCO.2015.60.9107 [PubMed] [CrossRef[]
19. Yothers G, O’Connell MJ, Allegra CJ, Kuebler JP, Colangelo LH, Petrelli NJ, et al. . Oxaliplatin As Adjuvant Therapy for Colon Cancer: Updated Results of NSABP C-07 Trial, Including Survival and Subset AnalysesJ Clin Oncol (2011) 29(28):3768–74.  10.1200/JCO.2011.36.4539 [PMC free article] [PubMed] [CrossRef[]
20. Twelves C, Scheithauer W, Mckendrick J, Seitz JF, Hazel GV, Wong A, et al. . Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacyAnn Oncol (2012) 23(5):1190–7.  10.1093/annonc/mdr366 [PubMed] [CrossRef[]
21. Böckelman C, Engelmann BE, Kaprio T, Hansen TF, Glimelius BJAO. Risk of recurrence in patients with colon cancer stage II and III: a systematic review and meta-analysis of recent literatureActa Oncol (2015) 54(1):5–16.  10.3109/0284186X.2014.975839 [PubMed] [CrossRef[]
22. André T, De GA, Vernerey D, Chibaudel B, Bonnetain F, Tijerasraballand A, et al. . Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC StudyJ Clin Oncol (2015) 33(35):4176–87.  10.1200/JCO.2015.63.4238 [PubMed] [CrossRef[]
23. Kuebler JP, Wieand HS, O’Connell MJ, Smith RE, Colangelo LH, Yothers G, et al. . Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07J Clin Oncol (2007) 25(16):2198–204.  10.1200/JCO.2006.08.2974 [PubMed] [CrossRef[]
24. Kidwell KM, Yothers G, Ganz PA, Land SR, Ko CY, Cecchini RS, et al. . Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01Cancer (2012) 118(22):5614–22.  10.1002/cncr.27593 [PMC free article] [PubMed] [CrossRef[]
25. André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. . Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trialJ Clin Oncol (2009) 27(19):3109–16.  10.1200/JCO.2008.20.6771 [PubMed] [CrossRef[]
26. Gao J, He Q, Li Y, Shen L, Hua D, Mao J. Clinical and T. Oncology: Polymorphism of TS 3’-UTR predicts survival of Chinese advanced gastric;cancer patients receiving first-line capecitabine plus paclitaxelClin Transl Oncol (2013) 15(8):619–25. 10.1007/s12094-012-0979-8 [PubMed] [CrossRef[]
27. Baek Y, Yi M. Factors Influencing Quality of Life during Chemotherapy for Colorectal Cancer Patients in South KoreaJ Korean Acad Nurs (2015) 45(4):604–12.  10.4040/jkan.2015.45.4.604 [PubMed] [CrossRef[]
28. Hermann CP, Looney SW. Determinants of quality of life in patients near the end of life: a longitudinal perspectiveOncol Nurs Forum (2011) 38(1):23–31.  10.1188/11.ONF.23-31 [PubMed] [CrossRef[]
29. Stiggelbout AM, Kunneman M, Baas-Thijssen MC, Neijenhuis PA, Loor AK, Jägers S, et al. . The EORTC QLQ-CR29 quality of life questionnaire for colorectal cancer: validation of the Dutch versionQual Life Res (2016) 25(7):1853–8.  10.1007/s11136-015-1210-5 [PMC free article] [PubMed] [CrossRef[]
30. Klinkhammerschalke M, Lindberg P, Koller M, Wyatt JC, Hofstädter F, Lorenz W, et al. . Direct improvement of quality of life in colorectal cancer patients using a tailored pathway with quality of life diagnosis and therapy (DIQOL): study protocol for a randomised controlled trialTrials (2015) 16(1):460.  10.1186/s13063-015-0972-y [PMC free article] [PubMed] [CrossRef[]
31. Arraras JI, Suárez J, Arias DLVF, Vera R, Asín G, Arrazubi V, et al. . The EORTC Quality of Life questionnaire for patients with colorectal cancer: EORTC QLQ-CR29 validation study for Spanish patientsClin Trans Oncol (2009) 11(3):160–4.  10.1007/s12094-011-0616-y [PubMed] [CrossRef[]

Articles from Frontiers in Oncology are provided here courtesy of Frontiers Media SA

Plaats een reactie ...

Reageer op "Chinese kruidencombinatie PRM1201 geeft in combinatie met chemotherapie na 3 jaar 9 procent betere ziektevrije overleving bij patienten met operabele darmkanker stadium III"

Gerelateerde artikelen

Gerelateerde artikelen

Chinese kruidencombinatie >> TCM - Traditionele Chinese >> ShenQi FuZheng Injectie aanvullend >> TCM - Traditionele Chinese >> Chinese Kruiden - TCM alleen >> Chinese kruiden - Shenqui >> Goshajinkigan - Japans kruidenmengsel >> Chinese kruiden: Injecties >>